Biocept Inc (BIOC)

1.83
0.26 12.44
NASDAQ : Health Care
Prev Close 2.09
Open 2.09
Day Low/High 1.70 / 2.09
52 Wk Low/High 0.56 / 2.76
Volume 6.00M
Avg Volume 1.89M
Exchange NASDAQ
Shares Outstanding 17.50M
Market Cap 36.57M
EPS -3.10
Div & Yield N.A. (N.A)

Latest News

Clinical Utility Of Biocept's Liquid Biopsy Platform Demonstrated In Study Results Presented At The 2016 San Antonio Breast Cancer Symposium

Clinical Utility Of Biocept's Liquid Biopsy Platform Demonstrated In Study Results Presented At The 2016 San Antonio Breast Cancer Symposium

High concordance of the Company's Target-Selectorâ„¢ platform enables real-time monitoring of key biomarkers in metastatic breast cancer, and provides an alternative when tissue biopsy is not an option

Biocept Presents Robust Analytical Validation Study Results For Its PD-L1 Liquid Biopsy Test At The 17th IASLC World Conference On Lung Cancer

Biocept Presents Robust Analytical Validation Study Results For Its PD-L1 Liquid Biopsy Test At The 17th IASLC World Conference On Lung Cancer

Results demonstrate high level of analytical sensitivity and specificity for the Company's non-invasive, clinically actionable biomarker test for immunotherapy

Study Results Presented At The 2016 ESMO Annual Congress Demonstrate Leading Clinical Performance With Biocept's CtDNA Liquid Biopsy Platform Vs. Tissue Biopsy

Study Results Presented At The 2016 ESMO Annual Congress Demonstrate Leading Clinical Performance With Biocept's CtDNA Liquid Biopsy Platform Vs. Tissue Biopsy

Target Selectorâ„¢ platform delivers 90% concordance and capability to rapidly detect EGFR, ALK, BRAF, and ROS1 alterations in non-small cell lung cancer patients

Biocept To Collaborate With Renowned Clinical Investigator Dr. Shilpa Gupta To Study The Utility Of Liquid Biopsy Testing In Bladder And Prostate Cancers

Biocept To Collaborate With Renowned Clinical Investigator Dr. Shilpa Gupta To Study The Utility Of Liquid Biopsy Testing In Bladder And Prostate Cancers

Observational study aimed at supporting the clinical utility of Biocept's tests for PD-L1 and androgen receptor expression

Biocept Expands Chinese Patent Protection Covering Key Technologies for Circulating Tumor Cell Capture and Analysis Used in Liquid Biopsy Tests

Biocept Expands Chinese Patent Protection Covering Key Technologies for Circulating Tumor Cell Capture and Analysis Used in Liquid Biopsy Tests

Fourteenth issued patent covers unique stain for detection of rare cells of interest including circulating tumor cells (CTCs)

Biocept To Present At Next Generation Dx Summit

Biocept To Present At Next Generation Dx Summit

Presentation to focus on identifying medically actionable biomarkers in cancer patients using liquid biopsy to analyze both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA)

Biocept Expands Distribution Of Liquid Biopsy Tests To The Philippines

Biocept Expands Distribution Of Liquid Biopsy Tests To The Philippines

Enters into agreement with HarlePhil Ventures, marking the Company's third announced international distribution partnership

Biocept Granted Japanese Patent Covering Microchannel And Antibody Capture

Biocept Granted Japanese Patent Covering Microchannel And Antibody Capture

Strengthens global intellectual property position with 13th issued patent covering the company's proprietary technology for the capture and detection of rare cells from biological fluids

Biocept Comments On Reimbursement Provisions In CMS' Final PAMA Rule

Biocept Comments On Reimbursement Provisions In CMS' Final PAMA Rule

Commends CMS for supporting innovation in diagnostics and transparency on future Medicare pricing

Biocept Launches Liquid Biopsy Immuno-Oncology PD-L1 Test

Biocept Launches Liquid Biopsy Immuno-Oncology PD-L1 Test

New test uses patient's blood sample to profile and monitor for PD-L1 expression, an important biomarker in immuno-oncology treatment decision making

High Sensitivity Of Biocept's Target Selector Blood-Based Liquid Biopsy Tests Featured In Two Abstracts At ASCO

High Sensitivity Of Biocept's Target Selector Blood-Based Liquid Biopsy Tests Featured In Two Abstracts At ASCO

Study data further support the clinical utility and validation of Biocept's CTC and ctDNA tests to profile and monitor biomarker status in patients diagnosed with cancer

Biocept Announces Master Services Agreement With Pharma Company To Develop Liquid Biopsy Tests

Biocept Announces Master Services Agreement With Pharma Company To Develop Liquid Biopsy Tests

Continues to execute on 2016 Company priority with second pharma company agreement

Biocept Launches Proprietary Liquid Biopsy Test To Detect RET Fusions In Patients With Lung Cancer

Biocept Launches Proprietary Liquid Biopsy Test To Detect RET Fusions In Patients With Lung Cancer

Detecting RET fusions can identify patients who may benefit from targeted therapy with tyrosine kinase inhibitors

Biocept Expands Intellectual Property Portfolio With 12th Granted Patent On Its Key Liquid Biopsy Technology

Biocept Expands Intellectual Property Portfolio With 12th Granted Patent On Its Key Liquid Biopsy Technology

This sixth U.S. patent covers unique method used for detection of rare cells including circulating tumor cells

Insider Trading Alert - BA, WLL And BIOC Traded By Insiders

Insider Trading Alert - BA, WLL And BIOC Traded By Insiders

Stocks with insider trader activity include BA, WLL and BIOC